Loading...
Protalix reports a transformational first quarter in 2020, closing a $43.7 million private placement and submitting a BLA for PRX-102 after completing the Phase III BRIDGE study.
Closed a $43.7 million private placement.
Completed Phase III BRIDGE study.
Submitted BLA for PRX-102.
Adapted quickly to the changing environment despite the COVID-19 pandemic.
Protalix is positioned for long-term success and looks forward to continuing momentum through the rest of this year and into 2021.
Analyze how earnings announcements historically affect stock price performance